Article Detail - JF Part B
Billing and Coding: MolDX: Minimal Residual Disease Testing for Colorectal Cancer
This coverage article has been created and published for notice under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).
Effective Date: October 18, 2020
Summary of Article: This Medicare contractor will provide limited coverage for ctDNA tests that detect minimum residual disease (MRD) in patients with a personal history of colorectal cancer.
Visit the Noridian Medicare Coverage Articles webpage to view the complete listing of locally hosted coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD.
Last Updated Thu, 10 Sep 2020 17:16:07 +0000